

# NHS Greater Glasgow and Clyde: New Medicines Decisions

In Scotland, a newly licensed medicine is routinely available in a health board only after it has been:

- accepted for use in NHSScotland by the Scottish Medicines Consortium (SMC), and
- accepted for use by the health board's Area Drug and Therapeutics Committee (ADTC).

All medicines accepted by SMC are available in Scotland, but may not be considered 'routinely available' within NHS Greater Glasgow and Clyde (NHSGG&C) because of available services and preferences.

'Routinely available' means that a medicine can be prescribed by the appropriately qualified person within a health board.

Each health board has an ADTC. The Greater Glasgow and Clyde ADTC is responsible for advising the NHSGG&C health board on all aspects of the use of medicines.

Medicines routinely available within NHSGG&C are usually included in the GGC Formulary. The Formulary is a list of medicines for use in the health board that has been agreed by ADTC in consultation with healthcare professionals to prescribe for common medical conditions. The GGC Formulary can help improve safety as prescribers are likely to become more familiar with the medicines included. Medicines included are consistent across the health board.

## How does NHSGG&C decide which new medicines to make routinely available for patients?

The ADTC in NHSGG&C will consider national and local guidance before deciding whether to make a new medicine routinely available.

## What national guidance does the ADTC consider?

- SMC advice: The SMC considers newly licensed medicines and advises health boards in Scotland whether they should be available. When SMC considers a new medicine for the NHS in Scotland
  - how well the medicine works,
  - which patients might benefit from it,
  - whether it is as good or better than medicines the NHS already uses to treat the medical condition, and
  - whether it is good value for money.
- In the table below, national guidance usually refers to SMC advice. Links to SMC advice for individual medicines are also included in the table.
- In some cases, other agencies may also provide guidance on how medicines should be used. For example, Healthcare Improvement Scotland issues alerts to advise if National Institute for Health and Care Excellence (NICE) Appraisals (NICE MTAs) are applicable in Scotland.

## What local guidance does the ADTC consider?

- Advice from local clinical experts who would be expected to prescribe a particular medicine, where that service is available in NHSGG&C.

## Why is a particular medicine not routinely available in NHSGG&C?

- This is usually because the medicine is not recommended for use in NHSScotland by the SMC.
- The medicine may not be routinely available in a health board, particularly in smaller health boards, because there is not a suitable specialist who may use the medicine.
- There may also be differences in which medicines are preferred in health boards. Sometimes SMC accepts more than one medicine for treating a specific medical condition. Clinical experts in each health board advise on preferred medicines to their formulary and advise the ADTC. Sometimes it is agreed that established medicines are a better choice than new medicines.

Medicine	Condition being treated	NHSGGC Decision	Date of decision
----------	-------------------------	-----------------	------------------

<b>amivantamab</b>	0 In combination with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon20 insertion mutations.	Routinely available in line with local or regional guidance	16/02/2026
Rybrevant® SMC2878			
<b>axicabtagene ciloleucel</b>	0 Treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 15/06/2026	16/02/2026
Yescarta® SMC2695			
<b>belantamab mafodotin</b>	0 in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 15/06/2026	16/02/2026
Blenrep SMC2727			
<b>budesonide</b>	0 Short-term treatment of mild to moderate acute ulcerative colitis limited to the rectum (ulcerative proctitis) in adult patients.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 20/04/2026	16/02/2026
Budenofalk® SMC2855			
<b>cabozantinib</b>	0 Monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 15/06/2026	16/02/2026
SMC2754			

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>ciclosporin</b>  Veizye®  SMC2873	Treatment of moderate to severe dry eye disease (keratoconjunctivitis sicca) in adult patients, which has not improved despite treatment with tear substitutes.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 20/04/2026	16/02/2026
<b>clascoterone</b>  Winlevi®  SMC2894	Topical treatment of acne vulgaris in patients 12 years of age and older.	Not routinely available as not recommended for use in NHSScotland	16/02/2026
<b>daratumumab</b>  Darzalex®  SMC2895	Monotherapy for the treatment of adult patients with smouldering multiple myeloma at high risk of developing multiple myeloma	Not routinely available as not recommended for use in NHSScotland	16/02/2026
<b>delgocitinib</b>  Anzupgo®  SMC2817	Treatment of moderate to severe chronic hand eczema (CHE) in adults for whom topical corticosteroids are inadequate or inappropriate.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 15/06/2026	16/02/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>donanemab</b>  Kisunla®  SMC2871	0 Treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease (AD) in adult patients that are apolipoprotein E ε4 (ApoE ε4) heterozygotes or non-carriers.	Not routinely available as not recommended for use in NHSScotland	16/02/2026
<b>dupilumab</b>  Dupixent®  SMC2896	0 Treatment of chronic spontaneous urticaria (CSU) in patients aged 12 years and older whose disease is not adequately controlled with H1 antihistamine treatment.	Not routinely available as not recommended for use in NHSScotland	16/02/2026
<b>durvalumab</b>  Imfinzi®  SMC2857	0 In combination with tremelimumab for the first-line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 20/04/2026	16/02/2026
<b>durvalumab</b>  Imfinzi  SMC2797	0 in combination with carboplatin and paclitaxel for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with: <ul style="list-style-type: none"> <li>•durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR)</li> <li>•durvalumab in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).</li> </ul>	Routinely available in line with local or regional guidance	16/02/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>eplontersen</b>  Wainzua®  SMC2755	Treatment of hereditary transthyretin-mediated amyloidosis (ATTRv amyloidosis) in adult patients with Stage 1 and 2 polyneuropathy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:  20/04/2026	16/02/2026
<b>exagamglogene autotemcel</b>  Casgevy®  SMC2852	Treatment of sickle cell disease in patients 12 years of age and older with recurrent vaso-occlusive crises who have the $\beta^S/\beta^S$ , $\beta^S/\beta^+$ or $\beta^S/\beta^0$ genotype, for whom haematopoietic stem cell transplantation is appropriate and a human leukocyte antigen matched related haematopoietic stem cell donor is not available.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:  20/04/2026	16/02/2026
<b>givinostat</b>  Duvyzat®  SMC2856	Treatment of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:  20/04/2026	16/02/2026
<b>guselkumab</b>  Tremfya®  SMC2850	Treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic treatment.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:  20/04/2026	16/02/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>guselkumab</b>  Tremfya® SMC2848	0 Treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, a biologic treatment, or a Janus kinase (JAK) inhibitor.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 20/04/2026	16/02/2026
<b>isatuximab</b>  Sarclisa® SMC2804	0 In combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 20/04/2026	16/02/2026
<b>maralixibat</b>  Livmarli® SMC2806	0 Treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 2 months of age and older.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 20/04/2026	16/02/2026
<b>marstacimab</b>  Hympavzi® SMC2759	0 for routine prophylaxis of bleeding episodes in patients 12 years of age and older, weighing at least 35 kg, with: •severe haemophilia A (congenital factor VIII deficiency, FVIII < 1%) without factor VIII inhibitors, or •severe haemophilia B (congenital factor IX deficiency, FIX < 1%) without factor IX inhibitors.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 20/04/2026	16/02/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>nivolumab</b>  Opdivo®  SMC2820	0 In combination with ipilimumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high colorectal cancer in the following setting: first-line treatment of unresectable or metastatic colorectal cancer.	Routinely available in line with local or regional guidance	16/02/2026
<b>Paclitaxel (weekly) in combination with trastuzumab plus pertuzumab</b>          NCMAG125	0 For the first-line treatment of adults with HER2-positive metastatic or locally recurrent unresectable breast cancer who are considered fit for treatment with pertuzumab plus trastuzumab plus a taxane	Routinely available in line with local or regional guidance	16/02/2026
<b>pirtobrutinib</b>  Jaypirca®  SMC2897	0 monotherapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have been previously treated with a Bruton's tyrosine kinase (BTK) inhibitor.	Not routinely available as not recommended for use in NHSScotland	16/02/2026
<b>progesterone</b>  Prometrium®  SMC2869	0 Prevention of miscarriage in women presenting with bleeding in the first trimester of pregnancy and have a history of recurrent miscarriages	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 20/04/2026	16/02/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>ribociclib</b> Kisqali® SMC2803	In combination with an aromatase inhibitor for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence. In pre- or perimenopausal women, or in men, the aromatase inhibitor should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/08/2026	16/02/2026
<b>Semaglutide</b> Wegovy SMC2497	An adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of • $\geq 30$ kg/m <sup>2</sup> (obesity), or • $\geq 27$ kg/m <sup>2</sup> to $< 30$ kg/m <sup>2</sup> (overweight) in the presence of at least one weight-related comorbidity.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 15/06/2026	16/02/2026
<b>serplulimab</b> Hetronifly® SMC2840	In combination with carboplatin and etoposide for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).	Not routinely available as not recommended for use in NHSScotland	16/02/2026
<b>sotatercept</b> Winrevair® SMC2831	In combination with other pulmonary arterial hypertension (PAH) therapies, for the treatment of PAH in adult patients with WHO Functional Class (FC) II to III, to improve exercise capacity.	Not routinely available as not recommended for use in NHSScotland	16/02/2026

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>tirzepatide</b>  Mounjaro®  SMC2653	0 For weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial Body Mass Index (BMI) of ≥30 kg/m <sup>2</sup> (obesity) or ≥27 kg/m <sup>2</sup> to <30 kg/m <sup>2</sup> (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:  15/06/2026	16/02/2026
<b>zolbetuximab</b>  Vyloy®  SMC2839	0 In combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:  20/04/2026	16/02/2026
<b>zuranolone</b>  Zurzuvae®  SMC2862	0 Treatment of moderate or severe postnatal depression (PND) in adults following childbirth.	Not routinely available as not recommended for use in NHSScotland	16/02/2026